DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Virtual Booth

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

DIGITAL CONTENT

7 NEWS #PharmaBuzz

media
7 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

5DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1619931-27-9, Gb002, (s)-n-(3-(1-((6-(3,4-dimethoxyphenyl)pyrazin-2-yl)amino)ethyl)phenyl)-5-methylnicotinamide, Pk-10571, Seralutinib [usan], Gb-002

Molecular Formula

C₂₇H₂₇N₅O₃

Molecular Weight

469.5 g/mol

InChI Key

JHJNPOSPVGRIAN-SFHVURJKSA-N

FDA UNII

3P63ZTE3OY

1 2D Structure

Seralutinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[3-[(1S)-1-[[6-(3,4-dimethoxyphenyl)pyrazin-2-yl]amino]ethyl]phenyl]-5-methylpyridine-3-carboxamide

2.1.2 InChI

InChI=1S/C27H27N5O3/c1-17-10-21(14-28-13-17)27(33)31-22-7-5-6-19(11-22)18(2)30-26-16-29-15-23(32-26)20-8-9-24(34-3)25(12-20)35-4/h5-16,18H,1-4H3,(H,30,32)(H,31,33)/t18-/m0/s1

2.1.3 InChI Key

JHJNPOSPVGRIAN-SFHVURJKSA-N

2.1.4 Canonical SMILES

CC1=CC(=CN=C1)C(=O)NC2=CC=CC(=C2)C(C)NC3=NC(=CN=C3)C4=CC(=C(C=C4)OC)OC

2.1.5 Isomeric SMILES

CC1=CC(=CN=C1)C(=O)NC2=CC=CC(=C2)[C@H](C)NC3=NC(=CN=C3)C4=CC(=C(C=C4)OC)OC

2.2 Other Identifiers

2.2.1 UNII

3P63ZTE3OY

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. 1619931-27-9

2. Gb002

3. (s)-n-(3-(1-((6-(3,4-dimethoxyphenyl)pyrazin-2-yl)amino)ethyl)phenyl)-5-methylnicotinamide

4. Pk-10571

5. Seralutinib [usan]

6. Gb-002

7. 3p63zte3oy

8. N-[3-[(1s)-1-[[6-(3,4-dimethoxyphenyl)pyrazin-2-yl]amino]ethyl]phenyl]-5-methylpyridine-3-carboxamide

9. 3-pyridinecarboxamide, N-(3-((1s)-1-((6-(3,4-dimethoxyphenyl)-2-pyrazinyl)amino)ethyl)phenyl)-5-methyl-

10. Seralutinib [inn]

11. Unii-3p63zte3oy

12. Seralutinib [who-dd]

13. Chembl4650333

14. Schembl17324860

15. Gtpl10618

16. Ex-a5138

17. Who 11243

18. At11371

19. Pk10571

20. Structure 2a [wo2014110200a1]

21. Hy-109190

22. Cs-0116463

23. N-(3-((1s)-1-((6-(3,4-dimethoxyphenyl)-2-pyrazinyl)amino)ethyl)phenyl)-5-methyl-3-pyridinecarboxamide

2.4 Create Date

2015-03-23

3 Chemical and Physical Properties

Molecular Formula	C₂₇H₂₇N₅O₃
Molecular Weight	469.5 g/mol
XLogP3	3.7
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	8
Exact Mass	469.21138974 g/mol
Monoisotopic Mass	469.21138974 g/mol
Topological Polar Surface Area	98.3 Å²
Heavy Atom Count	35
Formal Charge	0
Complexity	667
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1